The 3q25 rs2305619 Polymorphism Associates With Microvascular Obstruction in STEMI
NCT ID: NCT03907722
Last Updated: 2019-04-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
217 participants
OBSERVATIONAL
2018-01-01
2018-09-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Association of Plasma PTX3 Concentration and Outcomes of STEMI
NCT03894176
Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
NCT01452139
The Relationship Between MPV,PDW,PFT and ST Segment Resolution in STEMI Patients Treated With Thrombolytic or Primary PCI
NCT03267199
Prognostic Value of the AMR Measured After PPCI in STEMI Patients
NCT05653765
Safety and Efficacy of Percutaneous Coronary Intervention Combined With Thrombolysis at Different Time
NCT03137212
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Genotypic variants
AA, AG and GG genotype
Long pentraxin 3
Primary PCI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Long pentraxin 3
Primary PCI
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indonesian Cardiovascular Research Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Surya Dharma
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Surya Dharma, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Indonesian Cardiovascular Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Indonesian Cardiovascular Research Center
Jakarta, DKI Jakarta, Indonesia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IndonesianCRC2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.